logo
logo
KALV stock ticker logo

KalVista Pharmaceuticals, Inc.

NASDAQ•KALV
CEO: Mr. Benjamin L. Palleiko
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-04-09
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Contact Information
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, 02142, United States
857-999-0075
www.kalvista.com
Market Cap
$1.37B
P/E (TTM)
-8.1
17.8
Dividend Yield
--
52W High
$26.76
52W Low
$9.83
52W Range
99%
Rank49Top 66.7%
3.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2026 Data

Revenue

$59.93M+0.00%
4-Quarter Trend

EPS

-$0.11+0.00%
4-Quarter Trend

FCF

$45.52M+0.00%
4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

EKTERLY Product Revenue Achieved Net product revenue reached $13.7M USD for the three/nine months ended September 30, 2025, following US launch.
Strong Cash Position Growth Cash, equivalents, restricted cash totaled $244.3M USD, marking a 799% increase from December 31, 2024.
Major Regulatory Milestones Met EKTERLY received FDA approval July 2025, followed by EU and Swiss regulatory authorizations in September 2025.
New Debt Issuance Secured Secured $139.4M USD proceeds from convertible notes issuance in September 2025 to fund operations and commercialization.

Risk Factors

Operating Loss Widened Nine months operating loss increased 16% to $(154.7M)$ USD, driven by initial commercialization expenses and costs.
SG&A Expenses Surged Selling, General, Administrative expenses rose 98% to $126.0M USD for nine months, supporting EKTERLY launch activities.
Net Loss Increased Significantly Net loss for nine months grew 30% to $(158.9M)$ USD, reflecting ongoing development and launch expenditures.
Increased Operating Cash Use Cash used in operating activities rose 39% to $(127.0M)$ USD for nine months, indicating higher burn rate.

Outlook

EKTERLY Commercial Expansion Anticipate continued operating losses supporting global EKTERLY commercialization and expansion into Switzerland pending reimbursement.
Pipeline Development Continues Development activities ongoing for pediatric EKTERLY expansion and preclinical research for oral Factor XIIa inhibitor program.
Sufficient Funding Runway Current capital resources expected to fund operations for at least the next twelve months from report issuance date.
Fiscal Year Change Implemented Fiscal year end changing from April 30 to December 31, effective December 31, 2025, creating transition period.

Peer Comparison

Revenue (TTM)

RIGL stock ticker logoRIGL
$294.28M
+64.1%
RGNX stock ticker logoRGNX
$170.44M
+104.5%
FDMT stock ticker logoFDMT
$85.21M
+230194.6%

Gross Margin (Latest Quarter)

MGTX stock ticker logoMGTX
99.4%
+33.5pp
GOSS stock ticker logoGOSS
98.4%
+0.0pp
FDMT stock ticker logoFDMT
97.7%
-52486.7pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
KOD$2.31B-10.1-255.4%16.8%
KALV$1.37B-8.1-444.4%84.7%
OLMA$1.23B-7.9-42.9%0.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026
|
EPS:-$0.41
|
Revenue:$38.33M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data